Health and Healthcare
Amgen And Genentech: Can Clinton Do What Competition Could Not?
Published:
Over the last five years, the shares of Genentech (DNA) have risen about 275%. Shares in Amgen (AMGN) are not up as much but they have performed about as well as the Dow.
Is it any wonder? Genentech’s revenue in 2000 was $1.376 billion. For the most recent trailing twelve months that figure was up to $8.462 billion. Over the same period, Amgen’s revenue has gone from $3.629 billion to $13.704 billion.
The two companies have had significant success developing treatment for a range of diseases from certain cancers to osteoporosis. Morningstar estimates that Amgen has five blockbuster drugs in late stage trials.
The company’s have such strong margins and pipelines that they trade at significant premiums to Big Pharma companies like Pfizer (PFE) and Merck (MRK).
But, the US government may be stepping in to do what competition could not–open the door to generic competition more quickly. Hillary Clinton is proposing legislation to allow generics firms to make cheaper versions of products from the biotech companies.
Biotech firms argue that their treatments are complex and cannot be, in most cases, replicated by generics companies without lengthy clinical trials. The generics firms claim that the drugs are not so complex and that they need faster approval of their versions by the FDA.
As the pressure for lower health care costs mounts, the large biotech firms could face an increasing squeeze on their remarkable revenue growth. Something that their competitors were unable to do.
Douglas A. McIntyre can be reached at [email protected]. He does not own securities in companies that he writes about.
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.